FOXP1 Potentiates Wnt/β-catenin Signaling in Diffuse Large B Cell Lymphoma
Overview
Physiology
Science
Authors
Affiliations
The transcription factor FOXP1 (forkhead box protein P1) is a master regulator of stem and progenitor cell biology. In diffuse large B cell lymphoma (DLBCL), copy number amplifications and chromosomal translocations result in overexpression of FOXP1. Increased abundance of FOXP1 in DLBCL is a predictor of poor prognosis and resistance to therapy. We developed a genome-wide, mass spectrometry-coupled, gain-of-function genetic screen, which revealed that FOXP1 potentiates β-catenin-dependent, Wnt-dependent gene expression. Gain- and loss-of-function studies in cell models and zebrafish confirmed that FOXP1 was a general and conserved enhancer of Wnt signaling. In a Wnt-dependent fashion, FOXP1 formed a complex with β-catenin, TCF7L2 (transcription factor 7-like 2), and the acetyltransferase CBP [CREB (adenosine 3',5'-monophosphate response element-binding protein)-binding protein], and this complex bound the promoters of Wnt target genes. FOXP1 promoted the acetylation of β-catenin by CBP, and acetylation was required for FOXP1-mediated potentiation of β-catenin-dependent transcription. In DLBCL, we found that FOXP1 promoted sensitivity to Wnt pathway inhibitors, and knockdown of FOXP1 or blocking β-catenin transcriptional activity slowed xenograft tumor growth. These data connect excessive FOXP1 with β-catenin-dependent signal transduction and provide a molecular rationale for Wnt-directed therapy in DLBCL.
Telomemore enables single-cell analysis of cell cycle and chromatin condensation.
Yakovenko I, Mihai I, Selinger M, Rosenbaum W, Dernstedt A, Groning R Nucleic Acids Res. 2025; 53(3).
PMID: 39878215 PMC: 11775621. DOI: 10.1093/nar/gkaf031.
miRNA‑22‑3p inhibits cell viability and metastasis of nasopharyngeal carcinoma by targeting FOXP1.
Jin Y, Wang Z, Liang Y, Jiang Y, Yuan F, Zhang T Oncol Lett. 2024; 29(2):96.
PMID: 39697977 PMC: 11653248. DOI: 10.3892/ol.2024.14842.
Long B, Wang Y, Hao S, Shi G Am J Cancer Res. 2024; 14(9):4633-4651.
PMID: 39417189 PMC: 11477815. DOI: 10.62347/KMWB5164.
Ham A, Chang A, Li H, Bain J, Goldman J, Sulzer D Mol Psychiatry. 2024; 30(2):810-824.
PMID: 39237724 DOI: 10.1038/s41380-024-02741-z.
Wang C, Fu W, Zhang Y, Hu X, Xu Q, Tong X Biol Direct. 2024; 19(1):47.
PMID: 38886753 PMC: 11184854. DOI: 10.1186/s13062-024-00488-9.